Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Approved to Launch HER-2 Cancer Adjuvant in China

publication date: May 7, 2020

CANbridge Pharma of Beijing announced China's NMPA approved the launch of Nerlynx® (neratinib) as an extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer. Patients must have previously received adjuvant trastuzumab therapy. Although trastuzumab has been shown to reduce recurrence in HER2-positive breast cancer following surgery, up to 25% of trastuzumab patients experience a return of their disease. In 2018, CANbridge in-licensed greater China rights to Nerlynx from Puma Pharma of the US in a $70 million agreement. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital